论文部分内容阅读
研究目的为确定一种用于治疗前列腺癌和心血管疾病的高选择性内皮素Ａ受体拮抗剂阿曲生坦(ａｔｒａｓｅｎｔａｎ)单剂量及多剂量的药代动力学。采用随机、安慰剂对照、单剂量和多剂量研究口服阿曲生坦的Ⅰ期临床试验。在研究第 1天及第 3～ 9天 ,给予健康男性志愿者单剂量 1,5
The aim of the study was to determine single and multiple dose pharmacokinetics of atrasentan, a highly selective endothelin A receptor antagonist for the treatment of prostate cancer and cardiovascular disease. A randomized, placebo-controlled, single-dose and multi-dose study of toxeitan in phase I clinical trials. On study day 1 and day 3 to day 9, healthy male volunteers were given a single dose of 1,5